Cynosure (NSDQ:CYNO) said today it won Chinese FDA clearance for its Icon aesthetic system, which is now cleared for multiple aesthetic indications. The system is now cleared in China for facial vessel and pigment clearance, wrinkle reduction, hair removal and scar and stretch mark treatment, the Westford, Mass.-based company said. “Cynosure was the 1st U.S. aesthetic laser […]
Integrated Endoscopy said today it tapped Brad Sharp as its new prez & CEO, as well as joining the company’s board. The company said it is making the move with Sharp in preparation of the launch of its Nevis single-use arthroscope, which is slated for early 2017. The company said it also named Rob Cripe […]
Novartis pharma head Epstein steps away, most recent loss in string of top-level turnovers Novartis (NYSE:NVS) is facing an upheaval in its top management, seeing 7 departures over the last 5 months as shares fell 25% since last July. Last week, Novartis pharmaceuticals head David Epstein quit as his division was split up. Earlier in the month, U.S. […]
Cynosure (NSDQ:CYNO) said today it won FDA 510(k) clearance for its 1064 nm PicoSure laser delivery system designed for tattoo removal. The next-gen laser delivery system has improved multi-wavelength laser technology designed to remove the “full color spectrum of tattoo inks” in less treatments than previous versions, the Westford, Mass.-based company said. “PicoSure is widely […]
MASSDEVICE ON CALL — In the pre-Obamacare world, medical device companies were able to price their products at a premium, justified by improvements in quality that were in some cases marginal. But premium pricing "typically becomes an easy target for disruption through product innovation in many other technology industries, especially when the market place is crowded with competitors," writes Mohit Kaushal, a partner at Aberdare Ventures in San Francisco.